As of 2025-09-18, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -13.40. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 400.39 mil USD. TBPH's TTM EBITDA according to its financial statements is -29.87 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 4.6x - 9.3x | 5.2x |
| Forward P/E multiples | 6.0x - 6.7x | 6.2x |
| Fair Price | 2.53 - 2.11 | 2.69 |
| Upside | -82.0% - -85.0% | -80.9% |
| Date | EV/EBITDA |
| 2025-09-15 | -13.99 |
| 2025-09-12 | -13.82 |
| 2025-09-11 | -12.81 |
| 2025-09-10 | -12.71 |
| 2025-09-09 | -12.91 |
| 2025-09-08 | -13.18 |
| 2025-09-05 | -13.23 |
| 2025-09-04 | -13.40 |
| 2025-09-03 | -12.87 |
| 2025-09-02 | -13.05 |
| 2025-08-29 | -13.12 |
| 2025-08-28 | -13.27 |
| 2025-08-27 | -12.98 |
| 2025-08-26 | -12.98 |
| 2025-08-25 | -12.97 |
| 2025-08-22 | -13.17 |
| 2025-08-21 | -12.75 |
| 2025-08-20 | -12.29 |
| 2025-08-19 | -12.39 |
| 2025-08-18 | -12.66 |
| 2025-08-15 | -11.89 |
| 2025-08-14 | -11.53 |
| 2025-08-13 | -10.66 |
| 2025-08-12 | -9.81 |
| 2025-08-11 | -8.94 |
| 2025-08-08 | -9.14 |
| 2025-08-07 | -8.62 |
| 2025-08-06 | -8.56 |
| 2025-08-05 | -8.41 |
| 2025-08-04 | -8.63 |
| 2025-08-01 | -8.09 |
| 2025-07-31 | -8.53 |
| 2025-07-30 | -8.38 |
| 2025-07-29 | -8.31 |
| 2025-07-28 | -8.36 |
| 2025-07-25 | -8.31 |
| 2025-07-24 | -8.48 |
| 2025-07-23 | -8.77 |
| 2025-07-22 | -8.65 |
| 2025-07-21 | -8.85 |
| 2025-07-18 | -8.68 |
| 2025-07-17 | -9.31 |
| 2025-07-16 | -9.36 |
| 2025-07-15 | -9.15 |
| 2025-07-14 | -9.05 |
| 2025-07-11 | -8.77 |
| 2025-07-10 | -9.04 |
| 2025-07-09 | -9.26 |
| 2025-07-08 | -8.63 |
| 2025-07-07 | -8.78 |